LY Qiao, J Lu, HY Huang. Clinical neurorestorative progress in stroke. J Neurorestoratol. 2015, 3: 63-71.
HY Huang, W Young, L Chen, et al. Clinical cell therapy guidelines for neurorestoration (IANR/ CANR 2017). Cell Transplant. 2018, 27(2): 310-324.
L Chen, HT Xi, HY Huang, et al. Multiple cell transplantation based on an intraparenchymal approach for patients with chronic phase stroke. Cell Transplant. 2013, 22(Suppl 1): S83-S91.
GK Steinberg, D Kondziolka, LR Wechsler, et al. Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a phase 1/2a study. Stroke. 2016, 47(7): 1817-1824.
GK Steinberg, D Kondziolka, LR Wechsler, et al. Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study. J Neurosurg. 2018: 1-11.
K Prasad, A Sharma, A Garg, et al. Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial. Stroke. 2014, 45(12): 3618-3624.
DC Hess, LR Wechsler, WM Clark, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017, 16(5): 360-368.
SI Savitz, D Yavagal, G Rappard, et al. A phase 2 randomized, sham-controlled trial of internal carotid artery infusion of autologous bone marrow-derived ALD-401 cells in patients with recent stable ischemic stroke (RECOVER-stroke). Circulation. 2019, 139(2): 192-205.
FD Lublin, JD Bowen, J Huddlestone, et al. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. Mult Scler Relat Disord. 2014, 3(6): 696-704.
SK Oh, KH Choi, JY Yoo, et al. A phase III clinical trial showing limited efficacy of autologous mesenchymal stem cell therapy for spinal cord injury. Neurosurgery. 2016, 78(3): 436-447.
WJ Rah, YH Lee, JH Moon, et al. Neuroregenerative potential of intravenous G-CSF and autologous peripheral blood stem cells in children with cerebral palsy: a randomized, double-blind, cross-over study. J Transl Med. 2017, 15(1): 16.
AD Levi, KD Anderson, DO Okonkwo, et al. Clinical outcomes from a multi-center study of human neural stem cell transplantation in chronic cervical spinal cord injury. J Neurotrauma. 2019, 36(6): 891-902.
HY Huang, L Chen, HT Xi, et al. Olfactory ensheathing cells transplantation for central nervous system diseases in 1255 patients (in Chinese). Chin J Reparative Reconstr Surg. 2009, 23(1): 14-20.
HY Huang, L Chen, HT Xi, et al. Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: a controlled pilot study. Clin Transplant. 2008, 22(6): 710-718.
L Chen, HY Huang, HT Xi, et al. Intracranial transplant of olfactory ensheathing cells in children and adolescents with cerebral palsy: a randomized controlled clinical trial. Cell Transplant. 2010, 19(2): 185-191.
L Danielyan, R Schäfer, A von Ameln-Mayerhofer, et al. Intranasal delivery of cells to the brain. Eur J Cell Biol. 2009, 88(6): 315-324.
XL Guo, X Wang, Y Li, et al. Olfactory ensheathing cell transplantation improving cerebral infarction sequela: a case report and literature review. J Neurorestoratol. 2019, 7(2): 82-88.
GS Mao, YL Wang, XL Guo, et al. Neurorestorative effect of olfactory ensheathing cells and Schwann cells by intranasal delivery for patients with ischemic stroke: design of a multicenter randomized double-blinded placebo-controlled clinical study. J Neurorestoratol. 2018, 1(1): 97-103.
HY Huang, HM Wang, L Chen, et al. Influence factors for functional improvement after olfactory ensheathing cell transplantation for chronic spinal cord injury. Chin J Reparative Reconstr Surg. 2006, 20(4): 434-438.
HJ Chen, QJ Tan, CJ Xie, et al. Application of olfactory ensheathing cells in clinical treatment of spinal cord injury: meta-analysis and prospect. J Neurorestoratol. 2019, 7(2): 70-81.
EH Holbrook, EM Wu, WT Curry, et al. Immunohistochemical characterization of human olfactory tissue. Laryngoscope. 2011, 121(8): 1687-1701.
L Chen, HY Huang, HT Xi, et al. A prospective randomized double-blind clinical trial using a combination of olfactory ensheathing cells and Schwann cells for the treatment of chronic complete spinal cord injuries. Cell Transplant. 2014, 23(Suppl 1): S35-S44.
H Saberi, P Moshayedi, HR Aghayan, et al. Treatment of chronic thoracic spinal cord injury patients with autologous Schwann cell transplantation: an interim report on safety considerations and possible outcomes. Neurosci Lett. 2008, 443(1): 46-50.
H Saberi, M Firouzi, Z Habibi, et al. Safety of intramedullary Schwann cell transplantation for postrehabilitation spinal cord injuries: 2-year follow-up of 33 cases. J Neurosurg: Spine. 2011, 15(5): 515-525.
XH Zhou, GZ Ning, SQ Feng, et al. Transplantation of autologous activated Schwann cells in the treatment of spinal cord injury: six cases, more than five years of follow-up. Cell Transplant. 2012, 21(Suppl 1): S39-S47.
CG van Horne, JE Quintero, JT Slevin, et al. Peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson's disease during deep brain stimulation surgery: 1-year follow-up study of safety, feasibility, and clinical outcome. J Neurosurg. 2018, 129(6): 1550-1561.
SO Yazdani, M Hafizi, AR Zali, et al. Safety and possible outcome assessment of autologous Schwann cell and bone marrow mesenchymal stromal cell co-transplantation for treatment of patients with chronic spinal cord injury. Cytotherapy. 2013, 15(7): 782-791.
S Oraee-Yazdani, M Hafizi, A Atashi, et al. Co-transplantation of autologous bone marrow mesenchymal stem cells and Schwann cells through cerebral spinal fluid for the treatment of patients with chronic spinal cord injury: safety and possible outcome. Spinal Cord. 2016, 54(2): 102-109.
A Ramón-Cueto, M Nieto-Sampedro. Regeneration into the spinal cord of transected dorsal root axons is promoted by ensheathing glia transplants. Exp Neurol. 1994, 127(2): 232-244.